Amyloidosis cutis dyschromica in two female siblings: cases report

Wenlin Yang*, Yangyang Lin, Jian Yang, Wensheng Lin

Abstract

Background: Cutaneous amyloidosis has been classified into primary cutaneous amyloidosis (PCA, OMIM #105250), secondary cutaneous amyloidosis and systemic cutaneous amyloidosis. PCA is the deposition of amyloid in previously apparent normal skin without systemic involvement. Amyloidosis cutis dyschromica (ACD) is a rare distinct type of PCA. Here, the unique clinical and histological findings of two Chinese female siblings with ACD were described.

Cases presentations: Patient 1 was a 34-year-old female, presented with mildly pruritic, diffuse mottled hyperpigmentation and hypopigmentation. The lesions involved all over the body since she was 10 years old. There were a few itchy blisters appearing on her arms, lower legs and truck, especially on the sun-exposed areas in summer. Some hypopigmented macules presented with slight atrophy. Patient 2 was 39-year-old, the elder sister of patient 1. She had similar skin lesions since the same age as the former. The atrophy and blisters on the skin of the patient with amyloidosis cutis dyschromica have not been described in previous literature. Histological examinations of the skin biopsies taken from both patients revealed amyloid deposits in the whole papillary dermis. Depending on the histological assessment, the two cases were diagnosed as amyloidosis cutis dyschromica.

Conclusion: The two cases suggest that the atrophy and blisters may be the uncommon manifestations of amyloidosis cutis dyschromica. It alerts clinicians to consider the possibility of ACD when meeting patients with cutaneous dyschromia. Skin biopsy is essential and family consultation of genetic investigation is very important in such cases.
symmetrical pattern. In addition, some hypopigmented macules presented with slight atrophy. The skin lesions were more pronounced on the lower legs (Figure 1A), back and waist (Figure 1B, 1C), and the larger hypopigmented lesions were seen mainly on the lower legs. Individual blisters which were negative Nikolsky sign occurred on the upper arm (Figure 1D). The neck and face were only mildly affected. There was no apparent papular, erythema and telangiectasia. The dorsa of both hands and feet were uninvolved. The hair, teeth, nails, the mucosa of the mouth, palms, soles and vulva were normal-looking. The hearing was normal. Systemic examinations were unremarkable. The mental and developmental milestones of the patients were normal.

Patient 2 was 39-year-old, the elder sister of patient 1. Her stature was 149 cm. She had similar skin lesions since the same age as patient 1. She presented with diffuse hyperpigmentation and spotted hypopigmentation especially on the lower legs and the waist. She had less skin lesions than Patient 1, and did not show any pigmentation on the face or neck. Likewise, her systemic examination was unremarkable.

They were born to nonconsanguineous parents. Their mother had a small quantity of asymptomatic hypopigmented spots ranging from 2 to 4 mm in diameter on bilateral lower legs and back which were not explored further. Other family members have not similar manifestation.

The results of skin biopsies taken from the lower legs in both patients were similar. The pathological section with haematoxylin and eosin stain revealed hyperkeratotic epidermis and papillary dermis fully filled with amorphous eosinophilic masses (Figure 2A). The Congo red staining was positive to eosinophilic masses (Figure 2B), which indicated a deposit of amyloid substance. If using polarized light microscope, eosinophilic masses stained with Congo red will show the characteristic of apple-green birefringence. Additional staining with a marker of HMB-45, in order to differentiate ACD from other diseases with the characteristics of cutaneous dyschromia, was negative (Figure 2C).

Other results of routine laboratory examinations including routine blood test, biochemical profile, urine protein excretion and chest X-ray, abdominal ultrasound were normal in both patients.

Based on the clinical and pathological findings, the diagnosis of amyloidosis cutis dyschromica (ACD) was made for both patients. Topical tazarotene was prescribed without obvious improvement over a 1-month follow-up period.

Discussion
PCA includes the more common papular (lichen amyloidosis) and macular and nodular or tumefactive form [1]. ACD is a more uncommon subtype of PCA and was initially described by Morishima in 1970. This disorder is characterized by the following features: (i) dotted, reticular hypopigmentation with hypopigmented spots without papulation almost all over the body; (ii) no or little itchy sensation; (iii) onset before puberty; and (iv) small foci of amyloid closely under the epidermis [2,3]. Eng et al [4] first reported family survey with ACD. Huang et al [5] and Choonhakarn et al [6] collected four cases from two families and six cases from three families respectively. Vijaikumar et al [7] reported two siblings with ACD.

Our cases presented with reticular hyperpigmentation with hypopigmented spots, which were generalized distribution and onset before puberty. The amyloid deposits were limited to the subepidermal region, without other cutaneous and systemic involvement. All of these were ranged ACD. Besides, in our patients, there are some clinical features, dotty atrophy and blisters of skin, that have not been described in previous literature of ACD.
Besides ACD, there are many other diseases with the characteristics of cutaneous dyschromia, including dyschromatosis universalis hereditaria, xeroderma pigmentosum and poikyloderma-like amyloidosis. It is necessary to differentiate these diseases [3,8-10]. Amyloid deposits can not be found in the skin of the patients with dyschromatosis universalis hereditaria and xeroderma pigmentosum. ACD and poikyloderma-like cutaneous amyloidosis have similar clinical features. Poikyloderma-like cutaneous amyloidosis is characterised by the presence of poikylodermic lesions, lichenoid papules and blisters especially located on the limbs and appears in adult life. It is associated with photosensitivity, low height and a certain degree of palmo-plantar keratoderma. A few clinical features are overlapping between ACD and poikyloderma-like amyloidosis. In our patients, there were dotty atrophy and vesicles of skin but no telangiectasia and palmo-plantar keratoderma. Also their statures were normal. Hence we do not know whether the two type of PCA belong to the same kind of disease, or there is a new subtype between the two types?

The etiology of PCA remains unknown, but it is believed to be multifactorial. Our patients are two female siblings and their mother has suspicious ACD. Owing to the familial aggregation, it suggests that genetic factors may play an important role in its pathogenesis. Vijaikumar et al [7] proposed that genetic factors may lead to UVB sensitivity and DNA repair defects. This repeated damage to the keratinocytes results in the production of amyloid materials in the skin [1]. However, genetic loci for familial PCA (FPCA) have not been identified so far. The clinical features of patients with PCA are varied. Whether genetic variability determines the forms of expression of the disease remains unknown.

Although the aetiology of PCA is not clear, some researches still help to explore the skin disorder whether linked to genetic pathogenesis. Lin’s team [11] implied that a possible susceptibility locus for a subset of FPCA might exist on chromosome 1q23. By further experiments, an evidence of significant linkage to chromosome 5p13.1-q11.2 in a subset of FPCA was shown [12]. Lee et al [13] elucidated that evidence was lack to support for linkage of FPCA with the pericentromeric region of chromosome 10. Arita et al [14] indicated missense mutations of familial primary localized cutaneous amyloidosis (FPLCA) were located in the oncostatin M-specific receptor (OSMR) gene, which encodes oncostatin M-specific receptor beta (OSMRβ) – a component of the oncostatin M (OSM) type II receptor and the interleukin (IL)-31 receptor. Their OSMR data in individuals with FPLCA represented the first human germline mutations in this cytokine receptor complex. PCA can be caused by mutations in two biologically associated cytokine receptor genes located on chromosome 5 [15]. Novel IL31RA gene mutation and ancestral OSMR mutant allele provide an explanation for the genetic pathogenesis of PCA. Tanaka’s study [16] demonstrated that most changes of gene expression revealed alterations in epidermal differentiation and proliferation consistent with lichenification. They also found a reduction of several interfollicular keratinocyte stem cell markers in FPLCA skin. Their results promoted the molecular skin pathological progression on FPLCA.

The treating method of PCA is poor. topical corticosteroids, tretinoin, cryotherapy and carbon dioxide laser have varying effects. Systemic acitretin have been applied and suggest a good response [17].

Conclusion
Our cases suggest that the atrophy and blisters may be the uncommon manifestations of amyloidosis cutis dyschromica. It alerts clinicians to consider the possibility of ACD when meeting patients with cutaneous dyschromia. Skin biopsy is essential and family consultation of genetic investigation is very important in such cases.

Consent
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
ACD: Amyloidosis cutis dyschromica; PCA: primary cutaneous amyloidosis; FPLCA: familial primary localized cutaneous amyloidosis; HE: haematoxylin and eosin. HMB-45: human melanoma black 45; OSM: oncostatin M; OSMR: oncostatin M-specific receptor. OSMRβ: oncostatin M-specific receptor beta.

Acknowledgements
We are grateful to Dr. Hao Zhuofang and Dr. Huang Shizhang in the Pathology Department of our hospital for their contribution to this project.

Authors’ contributions
WLY drafted the manuscript and designed the case-study. YYL participated in the data collection, followed up and managed the patient. JY carried out the histological examination, diagnosed and investigated. WSL participated in the data collection. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 3 September 2010 Accepted: 15 February 2011
Published: 15 February 2011

References
1. Black MM, Gawkroder DJ, Seymour CA, Weismann K. Metabolic and nutritional disorders. In Textbook of Dermatology. Volume 3. 6th edition. Edited by: Champion RH, Burton JL, Burns DA, Breathnach SM. Oxford: Blackwell Science Ltd. 1998:2577-2677.
2. Morishima T: A clinical variety of localized cutaneous amyloidosis characterized by dyschromia (amyloidosis cutis dyschromica). Jpn J Dermatol Series B 1970, 80:43-52.
1. Moriwaki S, Nishigori C, Horiguchi Y, Imamura S, Toda K, Takebe H: Amyloidosis cutis dyschromica: DNA repair reduction in the cellular response to UV light. *Arch Dermatol* 1992, 128(7):966-970.

2. Eng AM, Cogan L, Gunnar RM, Blekys: Familial generalized dyschromic amyloidosis cutis. *J Cutan Pathol* 1976, 3(2):102-108.

3. Huang WH, Wu CY, Yu CP, Chang CP: Amyloidosis cutis dyschromica: four cases from two families. *Int J Dermatol* 2009, 48(5):518-521.

4. Choonhakarn C, Wittayachanyapong S: Familial amyloidosis cutis dyschromica: six cases from three families. *J Dermatol* 2002, 29(7):439-442.

5. Vijaikumar M, Thappa DM: Amyloidosis cutis dyschromica in two siblings. *Clin Exp Dermatol* 2001, 26(8):674-676.

6. Wu CY, Huang WH: Two Taiwanese siblings with dyschromatosis universalis hereditaria. *Clin Exp Dermatol* 2009, 34(8):e666-e669.

7. Ogino A, Tanaka S: Poikiloderma-like cutaneous amyloidosis. Report of a case and review of the literature. *Dermatologica* 1977, 155(5):301-309.

8. Lin MW, Lee DD, Lin CH, Huang CY, Wong CK, Chang YT, Liu HN, Hsiao KJ, Tsai SF: Suggestive linkage of familial primary cutaneous amyloidosis to a locus on chromosome 1q23. *Br J Dermatol* 2005, 152(1):29-36.

9. Lee DD, Lin MW, Chen K, Huang CY, Liu MT, Wang CR, Chang YT, Liu HN, Liu TT, Wong CK, Tsai SF: Genome-wide scan identifies a susceptibility locus for familial primary cutaneous amyloidosis on chromosome 1p31.1-q12. *Br J Dermatol* 2006, 155(6):1201-1208.

10. Lee DD, Huang JF, Wong CK, Gagel RF, Tsai SF: Genetic heterogeneity of familial primary cutaneous amyloidosis: lack of evidence for linkage with the chromosome 10 pericentromeric region in Chinese families. *J Invest Dermatol* 1996, 107(1):30-33.

11. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, Odashiro M, Odashiro DN, Hase-Neto G, Hans NR, Holder MV, Bhogal BS, Hartshorne ST, Akiyama M, Shimizu H, McGrath JA: Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. *Am J Hum Genet* 2008, 82(1):73-80.

12. Lin MW, Lee DD, Liu TT, Lin YF, Chen SY, Huang CC, Weng HY, Liu YF, Tanaka A, Arita K, Lai-Cheong J, Palsson F, Chang YT, Wong CK, Matsuura I, McGrath JA, Tsai SF: Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. *Eur J Hum Genet* 2010, 18(1):26-32.

13. Tanaka A, Lai-Cheong JE, van den Akker PC, Nagy N, Millington G, Diercks GF, van Voort Vader PC, Clements SE, Almarsi N, Techanukul T, Hide M, South AP, McGrath JA: The molecular skin pathology of familial primary localized cutaneous amyloidosis. *Exp Dermato* 2010, 19(5):416-423.

14. Ozcan A, Senol M, Aydin NE, Karaca S: Amyloidosis cutis dyschromica: a case treated with acitretin. *J Dermatol* 2005, 32(6):474-477.